All In Biotech

Drug Trial Radar · NCT05242484

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 577 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

577

Actual

Start

Sep 19, 2022

Primary completion

May 15, 2025

Study completion Mar 27, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Feb 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or more approved advanced therapy.

Conditions

  • Colitis, Ulcerative

Interventions

  • GuselkumabBiological

    Guselkumab will be administered as subcutaneous injection.

  • GolimumabBiological

    Golimumab will be administered as subcutaneous injection.

  • JNJ-78934804Biological

    JNJ-78934804 will be administered subcutaneously as per defined regimen.

  • PlaceboDrug

    Placebo will be administered as subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Clinical Remission at Week 48Time frame: Week 48

Locations

403 sites in 37 countries. Site status is shown where the registry gives one.

  • Valley Gastroenterology Medical Group

    Arcadia, California

  • Southern California Research Center

    Coronado, California

  • Om Research LLC

    Lancaster, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • University of California San Francisco

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado

  • Medical Research Center of Connecticut

    Hamden, Connecticut

  • Yale University

    New Haven, Connecticut

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Pioneer Research Solutions Inc.

    Coconut Creek, Florida

  • Digestive and Liver Disease Institute

    Kissimmee, Florida

  • Osceola Regional Hospital

    Kissimmee, Florida

  • Florida Research Center Inc.

    Lakewood Rch, Florida

  • University of Miami

    Miami, Florida

  • Gastroenterology Group Of Naples

    Naples, Florida

  • Omega Research Consultants

    Orlando, Florida

  • Synergy Clinical Research

    St. Petersburg, Florida

  • GCP Clinical Research

    Tampa, Florida

  • Atlanta Gastroenterology Associates

    Atlanta, Georgia

  • Gastroenterolgy Associates of Central GA

    Macon, Georgia

  • Atlanta Gastroenterology Associates 1

    Marietta, Georgia

  • Gastrointestinal Specialists of Georgia

    Marietta, Georgia

  • Gastroenterology Consultants

    Roswell, Georgia

  • Grand Teton Gastroenterology

    Idaho Falls, Idaho

  • IU Health University Hospital

    Indianapolis, Indiana

  • Gastroenterology of Southern Indiana

    New Albany, Indiana

  • Tri-State Gastroenterology Assoc

    Crestview Hills, Kentucky

  • University of Kentucky Chandler Medical Center

    Lexington, Kentucky

  • Jewish Hospital

    Louisville, Kentucky

  • Chevy Chase Clinical Research

    Chevy Chase, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Brigham And Women's Hospital

    Chestnut Hill, Massachusetts

  • Huron Gastroenterology Associates Center for Digestive Care

    Ypsilanti, Michigan

  • Washington University

    St Louis, Missouri

  • Las Vegas Medical Research

    Las Vegas, Nevada

  • Care Access Las Vegas

    Las Vegas, Nevada

  • Dartmouth Hitchcock

    Lebanon, New Hampshire

  • Weill Cornell Medical College

    New York, New York

  • Lenox Hill Hospital

    New York, New York

Showing 40 of 403 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.